CL2004000412A1 - Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar. - Google Patents

Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar.

Info

Publication number
CL2004000412A1
CL2004000412A1 CL200400412A CL2004000412A CL2004000412A1 CL 2004000412 A1 CL2004000412 A1 CL 2004000412A1 CL 200400412 A CL200400412 A CL 200400412A CL 2004000412 A CL2004000412 A CL 2004000412A CL 2004000412 A1 CL2004000412 A1 CL 2004000412A1
Authority
CL
Chile
Prior art keywords
treat
facilitate
pulmonary hypertension
hypertension
treat pulmonary
Prior art date
Application number
CL200400412A
Other languages
English (en)
Inventor
Angelo Constan David Alexander
Original Assignee
Pfizer Products Inc Sa Organiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz
Publication of CL2004000412A1 publication Critical patent/CL2004000412A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

USO DE UN AGONISTA SELECTIVO DEL RECEPTOR EP2 PARA TRATAR LA HIPERTENSION PULMONAR, FACILITAR LA FUSION DE ARTICULACIONES, FACILITAR LA REPARACION DE TENDONES Y LIGAMENTOS, REDUCIR LA APARICION DE FRACTURAS SECUNDARIAS, TRATAR LA NECROSIS VASCULAR, FACILITAR LA REPERACION DEL CARTILAGO, FACILITAR LA CURACION DEL HUESO DESPUES DEL TRANSPLANTE DE UN MIEMBRO, FACILITAR LA REGENERACION HEPATICA, FACILITAR LA CURACION DE HERIDAS, REDUCIR LA APARICION DE ULCERAS GASTRICA, TRTAR LA HIPERTENSION, FACILITAR EL CRECIMIENTO DEL ESMALTE DE LOS DIENTES O LAS UNAS DE LOS DEDOS DE LAS MANOS O DE LOS PIES, TRATAR UN GLAUCOMA, TRTAR LA HIPERTENSION OCULAR Y RECUPERAR LAS LESIONES PRODUCIDAS POR UNA ENFERMEDAD METASTASICA DE HUESO.
CL200400412A 2003-03-04 2004-03-02 Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar. CL2004000412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04

Publications (1)

Publication Number Publication Date
CL2004000412A1 true CL2004000412A1 (es) 2005-02-04

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400412A CL2004000412A1 (es) 2003-03-04 2004-03-02 Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar.

Country Status (14)

Country Link
EP (1) EP1601351A1 (es)
JP (1) JP2006519250A (es)
KR (1) KR20050105511A (es)
CN (1) CN1859903A (es)
AU (1) AU2004216898A1 (es)
BR (1) BRPI0408061A (es)
CA (1) CA2518193A1 (es)
CL (1) CL2004000412A1 (es)
MX (1) MXPA05009398A (es)
NZ (1) NZ541828A (es)
PL (1) PL378748A1 (es)
TW (1) TW200424176A (es)
WO (1) WO2004078169A1 (es)
ZA (1) ZA200506532B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP2422814A1 (en) * 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
EP3424507A1 (en) 2006-03-24 2019-01-09 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EP2059507B1 (en) 2006-07-28 2013-03-20 Pfizer Products Inc. Ep2 agonist
EP2679221B1 (en) * 2006-10-20 2020-09-23 Children's Medical Center Corporation Method to enhance tissue regeneration
KR101558193B1 (ko) * 2007-08-21 2015-10-12 세노믹스, 인코포레이티드 인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도
HUE042839T2 (hu) * 2008-03-12 2019-07-29 Ube Industries Piridilaminoecetsav vegyületek
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
HRP20160104T1 (hr) 2009-03-30 2016-03-25 Ube Industries Farmaceutski pripravak za liječenje ili prevenciju glaukoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
AU2010293410A1 (en) * 2009-09-11 2012-05-03 Ube Industries, Ltd. Substituted carbonyl compounds
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
JPWO2011030864A1 (ja) * 2009-09-11 2013-02-07 宇部興産株式会社 アニリン化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
EP2520570A4 (en) * 2009-12-25 2013-07-17 Ube Industries aminopyridine compound
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
US10111907B2 (en) 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
EP3785767A1 (en) 2011-12-02 2021-03-03 Fate Therapeutics, Inc. Enhanced stem cell composition
HK1210969A1 (en) * 2012-01-20 2016-05-13 奥克塞拉有限公司 Substituted heterocyclic compounds for disease treatment
US20140142092A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
JPWO2014157672A1 (ja) 2013-03-28 2017-02-16 宇部興産株式会社 置換ビアリール化合物
EP3143026B1 (en) 2014-05-13 2024-07-10 Novartis AG Compounds and compositions for inducing chondrogenesis
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
CN115636761B (zh) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 一种油溶性表面活性剂、驱油剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
WO1998027976A1 (en) * 1996-12-20 1998-07-02 Pfizer Inc. Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
MXPA05009398A (es) 2005-12-05
WO2004078169A8 (en) 2005-04-21
PL378748A1 (pl) 2006-05-15
KR20050105511A (ko) 2005-11-04
CN1859903A (zh) 2006-11-08
TW200424176A (en) 2004-11-16
JP2006519250A (ja) 2006-08-24
WO2004078169A1 (en) 2004-09-16
BRPI0408061A (pt) 2006-02-14
EP1601351A1 (en) 2005-12-07
AU2004216898A1 (en) 2004-09-16
NZ541828A (en) 2008-06-30
ZA200506532B (en) 2007-03-28
CA2518193A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
CL2004000412A1 (es) Uso de un compuesto antagonista selectivo del receptor ep2 para tratar hipertension pulmonar.
ECSP056037A (es) Agonista del receptor ep4, composiciones y procedimientos del mismo
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
ECSP045203A (es) Cicloalcanindoles con sustitución con flúor y su uso como antagonistas del receptor prostaglandina d2
NO20092101L (no) Okularinnretninger og fremgangsmåter for fremstilling og anvendelse derav.
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
AR035275A1 (es) Tieniloxipirimidinas n-heterociclil-sustituidas
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
ECSP066756A (es) Anticuerpo monoclonal específico m-csf y los usos del mismo
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
CO2021006482A2 (es) Ureas cíclicas
CR7928A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
WO2003047513A3 (en) Method for treating ocular hypertension
ATE415817T1 (de) Agrochemische formulierungen
EP1732484A4 (en) OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
DE60334905D1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
GT200500309A (es) Derivados de sulfonilbencilimidazol
EA200970192A1 (ru) Производные 5,6-бисарил-2-пиридин-карбоксамида, их получение и их применение в терапии в качестве антагонистов рецепторов уротензина ii
CY1105877T1 (el) Οφθαλμικες συνθεσεις πepιεχουσες συνepγιστικο συνδυασμο τριων πολυμepων
DOP2003000747A (es) Composiciones oftalmicas para el tratamiento de la hipertension ocular
EA200400399A1 (ru) Способы лечения легочных заболеваний